GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Called orforglipron, the results of a new clinical trial announced Thursday by manufacturer Eli Lilly suggest that the pill could be a breakthrough in a class of drugs called GLP-1 agonists ...

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

Patients using GLP-1 receptor agonists appear to have a lower risk of age-related macular degeneration and primary open-angle glaucoma. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs ...